Redefining malignant pleural mesothelioma types as a continuum uncovers immune-vascular interactions

EBioMedicine. 2019 Oct;48:191-202. doi: 10.1016/j.ebiom.2019.09.003. Epub 2019 Oct 21.

Abstract

Background: Malignant Pleural Mesothelioma (MPM) is an aggressive disease related to asbestos exposure, with no effective therapeutic options.

Methods: We undertook unsupervised analyses of RNA-sequencing data of 284 MPMs, with no assumption of discreteness. Using immunohistochemistry, we performed an orthogonal validation on a subset of 103 samples and a biological replication in an independent series of 77 samples.

Findings: A continuum of molecular profiles explained the prognosis of the disease better than any discrete model. The immune and vascular pathways were the major sources of molecular variation, with strong differences in the expression of immune checkpoints and pro-angiogenic genes; the extrema of this continuum had specific molecular profiles: a "hot" bad-prognosis profile, with high lymphocyte infiltration and high expression of immune checkpoints and pro-angiogenic genes; a "cold" bad-prognosis profile, with low lymphocyte infiltration and high expression of pro-angiogenic genes; and a "VEGFR2+/VISTA+" better-prognosis profile, with high expression of immune checkpoint VISTA and pro-angiogenic gene VEGFR2. We validated the gene expression levels at the protein level for a subset of five selected genes belonging to the immune and vascular pathways (CD8A, PDL1, VEGFR3, VEGFR2, and VISTA), in the validation series, and replicated the molecular profiles as well as their prognostic value in the replication series.

Interpretation: The prognosis of MPM is best explained by a continuous model, which extremes show specific expression patterns of genes involved in angiogenesis and immune response.

Keywords: Angiogenesis; French MESOBANK; Immunotherapy; MESOMICS project; Pleural mesothelioma.

MeSH terms

  • Biomarkers, Tumor
  • Disease Susceptibility*
  • Female
  • Gene Expression Profiling
  • Humans
  • Immunohistochemistry
  • Lung Neoplasms / diagnosis*
  • Lung Neoplasms / etiology*
  • Lung Neoplasms / pathology
  • Male
  • Mesothelioma / diagnosis*
  • Mesothelioma / etiology*
  • Mesothelioma / pathology
  • Mesothelioma, Malignant
  • Neovascularization, Pathologic / immunology*
  • Pleural Neoplasms / diagnosis*
  • Pleural Neoplasms / etiology*
  • Pleural Neoplasms / pathology
  • Transcriptome
  • Tumor Microenvironment / immunology*

Substances

  • Biomarkers, Tumor